117 related articles for article (PubMed ID: 8383683)
1. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin.
Behrendt N; Rønne E; Danø K
J Biol Chem; 1993 Mar; 268(8):5985-9. PubMed ID: 8383683
[TBL] [Abstract][Full Text] [Related]
2. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.
Ellis V; Danø K
Biochem J; 1993 Dec; 296 ( Pt 2)(Pt 2):505-10. PubMed ID: 8257443
[TBL] [Abstract][Full Text] [Related]
3. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.
Moser TL; Enghild JJ; Pizzo SV; Stack MS
Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):867-73. PubMed ID: 7537960
[TBL] [Abstract][Full Text] [Related]
4. Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor.
Casslén B; Nordengren J; Gustavsson B; Nilbert M; Lund LR
J Clin Endocrinol Metab; 1995 Sep; 80(9):2776-84. PubMed ID: 7673423
[TBL] [Abstract][Full Text] [Related]
5. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
Barnathan ES; Kuo A; Rosenfeld L; Karikó K; Leski M; Robbiati F; Nolli ML; Henkin J; Cines DB
J Biol Chem; 1990 Feb; 265(5):2865-72. PubMed ID: 2154462
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
7. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator.
Takano S; Gately S; Neville ME; Herblin WF; Gross JL; Engelhard H; Perricone M; Eidsvoog K; Brem S
Cancer Res; 1994 May; 54(10):2654-60. PubMed ID: 7513254
[TBL] [Abstract][Full Text] [Related]
8. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
Hajjar KA; Hamel NM
J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
[TBL] [Abstract][Full Text] [Related]
10. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
11. Unesterified long chain fatty acids inhibit the binding of single chain urokinase to the urokinase receptor.
al-Roof Higazi A; Aceto JF; Kniss D; Upson R; Cohen R; Dichek DA; Cines DB
Biochemistry; 1996 May; 35(21):6884-90. PubMed ID: 8639640
[TBL] [Abstract][Full Text] [Related]
12. Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Marutsuka K; Hasui Y; Asada Y; Naito S; Osada Y; Sumiyoshi A
Clin Exp Metastasis; 1995 Mar; 13(2):116-22. PubMed ID: 7882614
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
Ellis V
J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
[TBL] [Abstract][Full Text] [Related]
14. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.
Stoppelli MP; Corti A; Soffientini A; Cassani G; Blasi F; Assoian RK
Proc Natl Acad Sci U S A; 1985 Aug; 82(15):4939-43. PubMed ID: 2991901
[TBL] [Abstract][Full Text] [Related]
15. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
Ellis V; Whawell SA; Werner F; Deadman JJ
Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
[TBL] [Abstract][Full Text] [Related]
16. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynolds LM
J Natl Cancer Inst; 1997 May; 89(10):709-17. PubMed ID: 9168186
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.
Solberg H; Løber D; Eriksen J; Ploug M; Rønne E; Behrendt N; Danø K; Høyer-Hansen G
Eur J Biochem; 1992 Apr; 205(2):451-8. PubMed ID: 1374026
[TBL] [Abstract][Full Text] [Related]
18. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system.
Michaud-Levesque J; Rolland Y; Demeule M; Bertrand Y; Béliveau R
Biochim Biophys Acta; 2005 Apr; 1743(3):243-53. PubMed ID: 15843038
[TBL] [Abstract][Full Text] [Related]
20. Thrombin decreases the urokinase receptor and surface-localized fibrinolysis in cultured endothelial cells.
Li XN; Varma VK; Parks JM; Benza RL; Koons JC; Grammer JR; Grenett H; Tabengwa EM; Booyse FM
Arterioscler Thromb Vasc Biol; 1995 Mar; 15(3):410-9. PubMed ID: 7749851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]